<p>藥明康德（NASDAQ:MVIS - 獲取免費報告）於週三發佈了季度財報。這家電子製造商報告本季度每股收益為（$0.12），低於分析師一致預期的（$0.05），差距為（$0.07），FiscalAI 報道。藥明康德的股本回報率為負的 131.03%，淨利潤率為負的 3,354.08%。該公司本季度的收入為 22 萬美元，而一致預期為 300 萬美元。</p>
<h2>藥明康德價格表現</h2>
<ul>
<li>你發誓永遠不會買的三隻便士股票（但你還是會查看）</li>
</ul>
<p>週三交易時段，MVIS 股價下跌 0.01 美元，報 0.78 美元。該股票交易量為 4,007,852 股，而其平均交易量為 4,059,544 股。該公司的市值為 2.3815 億美元，市盈率為 -2.11，貝塔值為 1.21。藥明康德的 52 周低點為 0.65 美元，52 周高點為 1.73 美元。該公司的 50 日移動平均線為 0.84 美元，200 日移動平均線為 1.01 美元。</p>
<h2>分析師設定新目標價</h2>
<p>幾位股票分析師對該股發表了評論。D. Boral Capital 在 1 月 27 日的報告中重申了 “買入” 評級，並對藥明康德的股票設定了 3.00 美元的目標價。Weiss Ratings 在 12 月 29 日的研究報告中重申了對藥明康德的 “賣出（d-）” 評級。兩位投資分析師給予該股 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股目前的平均評級為 “持有”，一致目標價為 2.50 美元。</p>
<ul>
<li>藥明康德在空頭擠壓後能否保持勢頭？</li>
</ul>
<p><strong>查看我們最新的 MVIS 股票報告</strong></p>
<h2>機構投資者對藥明康德的看法</h2>
<p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。NewEdge Advisors LLC 在第一季度收購了藥明康德的新股份，價值約 56,000 美元。Focus Partners Wealth 在第一季度購買了藥明康德的新股份，價值約 32,000 美元。摩根大通在第二季度將其在藥明康德的持倉增加了 20.0%。摩根大通目前擁有 136,739 股該電子製造商的股票，價值 156,000 美元，此前在此期間又購買了 22,824 股。Rhumbline Advisers 在第二季度將其在藥明康德的持倉增加了 17.2%。Rhumbline Advisers 目前擁有 330,919 股該電子製造商的股票，價值 377,000 美元，此前在此期間又購買了 48,588 股。最後，保誠金融公司在第二季度將其在藥明康德的持倉增加了 77.4%。保誠金融公司目前擁有 30,520 股該電子製造商的股票，價值 35,000 美元，此前在上個季度又收購了 13,315 股。機構投資者持有該公司 30.90% 的股份。</p>
<h2>關於藥明康德</h2>
<p>（獲取免費報告）</p>
<p>藥明康德，Inc NASDAQ: MVIS 是一家專注於激光掃描和傳感解決方案的科技公司。成立於 1993 年，總部位於華盛頓州雷德蒙德，藥明康德開發了其專有的 PicoP® 掃描技術，該技術集成了微型激光器和微電機械系統（MEMS）鏡子，以創建高分辨率投影顯示和三維傳感系統。多年來，該公司建立了一系列專注於精密光學和基於激光的信號處理的專利和知識產權。</p>
<p>藥明康德產品的核心是其顯示平台，該平台支持緊湊、節能的投影，適用於增強現實（AR）頭戴設備、汽車環境中的抬頭顯示（HUD）以及消費電子應用，如微型投影儀。</p>
<h2>另請參閲</h2>
<ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>CSE: ALEN.U 正在瞄準快速增長的數字健康市場</li>
<li>新發現富銅的 “克拉肯” 區域</li>
<li>1,500 家銀行剛剛將你的銀行賬户交給了美聯儲</li>
<li>你的名字尚未在我們的保護名單上</li>
<li>白銀支付 20% 股息，外加 68% 股份增值</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVZJUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVZJUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
<p>在你考慮藥明康德之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而藥明康德並不在名單上。</p>
<p>雖然藥明康德目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

維視圖像

<p>Microvision（納斯達克代碼：MVIS）報告每股收益為（$0.12），低於預期$0.07。該公司的股本回報率為負的 131.03%，收入為 22 萬美元，遠低於 300 萬美元的預期。股價下跌至$0.78，市值為 2.3815 億美元。分析師的評級意見不一，普遍目標價為$2.50。機構投資者持有 30.90% 的股份。Microvision 專注於激光掃描和傳感解決方案，重點開發高分辨率投影顯示和 3D 傳感系統</p>

<p>Microvision (NASDAQ:MVIS - Get Free Report) issued its quarterly earnings results on Wednesday. The electronics maker reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.07), FiscalAI reports. Microvision had a negative return on equity of 131.03% and a negative net margin of 3,354.08%.The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $3.00 million.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:MVIS - 獲取免費報告）於週三發佈了季度財報。這家電子製造商報告本季度每股收益為（$0.12），低於分析師一致預期的（$0.05），差距為（$0.07），FiscalAI 報道。藥明康德的股本回報率為負的 131.03%，淨利潤率為負的 3,354.08%。該公司本季度的收入為 22 萬美元，而一致預期為 300 萬美元。</p>
</div><h2>Microvision Price Performance</h2>
<div class="lb-trans"><h2>藥明康德價格表現</h2>
</div><ul>
<li>The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)</li>
</ul>
<div class="lb-trans"><ul>
<li>你發誓永遠不會買的三隻便士股票（但你還是會查看）</li>
</ul>
</div><p>Shares of MVIS traded down $0.01 during trading hours on Wednesday, hitting $0.78. 4,007,852 shares of the stock were exchanged, compared to its average volume of 4,059,544. The firm has a market capitalization of $238.15 million, a P/E ratio of -2.11 and a beta of 1.21. Microvision has a fifty-two week low of $0.65 and a fifty-two week high of $1.73. The business has a 50-day moving average of $0.84 and a 200-day moving average of $1.01.</p>
<div class="lb-trans"><p>週三交易時段，MVIS 股價下跌 0.01 美元，報 0.78 美元。該股票交易量為 4,007,852 股，而其平均交易量為 4,059,544 股。該公司的市值為 2.3815 億美元，市盈率為 -2.11，貝塔值為 1.21。藥明康德的 52 周低點為 0.65 美元，52 周高點為 1.73 美元。該公司的 50 日移動平均線為 0.84 美元，200 日移動平均線為 1.01 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several equities analysts have commented on the stock. D. Boral Capital reissued a &#34;buy&#34; rating and issued a $3.00 target price on shares of Microvision in a report on Tuesday, January 27th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Microvision in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus price target of $2.50.</p>
<div class="lb-trans"><p>幾位股票分析師對該股發表了評論。D. Boral Capital 在 1 月 27 日的報告中重申了 “買入” 評級，並對藥明康德的股票設定了 3.00 美元的目標價。Weiss Ratings 在 12 月 29 日的研究報告中重申了對藥明康德的 “賣出（d-）” 評級。兩位投資分析師給予該股 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股目前的平均評級為 “持有”，一致目標價為 2.50 美元。</p>
</div><ul>
<li>Will MicroVision Maintain Its Momentum After the Short Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>藥明康德在空頭擠壓後能否保持勢頭？</li>
</ul>
</div><p><strong>View Our Latest Stock Report on MVIS</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 MVIS 股票報告</strong></p>
</div><h2>Institutional Investors Weigh In On Microvision</h2>
<div class="lb-trans"><h2>機構投資者對藥明康德的看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC acquired a new stake in Microvision during the first quarter worth approximately $56,000. Focus Partners Wealth bought a new position in shares of Microvision during the 1st quarter worth approximately $32,000. JPMorgan Chase &amp; Co. grew its position in shares of Microvision by 20.0% during the 2nd quarter. JPMorgan Chase &amp; Co. now owns 136,739 shares of the electronics maker's stock worth $156,000 after buying an additional 22,824 shares during the period. Rhumbline Advisers grew its position in shares of Microvision by 17.2% during the 2nd quarter. Rhumbline Advisers now owns 330,919 shares of the electronics maker's stock worth $377,000 after buying an additional 48,588 shares during the period. Finally, Prudential Financial Inc. increased its stake in shares of Microvision by 77.4% in the 2nd quarter. Prudential Financial Inc. now owns 30,520 shares of the electronics maker's stock valued at $35,000 after acquiring an additional 13,315 shares in the last quarter. Institutional investors own 30.90% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。NewEdge Advisors LLC 在第一季度收購了藥明康德的新股份，價值約 56,000 美元。Focus Partners Wealth 在第一季度購買了藥明康德的新股份，價值約 32,000 美元。摩根大通在第二季度將其在藥明康德的持倉增加了 20.0%。摩根大通目前擁有 136,739 股該電子製造商的股票，價值 156,000 美元，此前在此期間又購買了 22,824 股。Rhumbline Advisers 在第二季度將其在藥明康德的持倉增加了 17.2%。Rhumbline Advisers 目前擁有 330,919 股該電子製造商的股票，價值 377,000 美元，此前在此期間又購買了 48,588 股。最後，保誠金融公司在第二季度將其在藥明康德的持倉增加了 77.4%。保誠金融公司目前擁有 30,520 股該電子製造商的股票，價值 35,000 美元，此前在上個季度又收購了 13,315 股。機構投資者持有該公司 30.90% 的股份。</p>
</div><h2>About Microvision</h2>
<div class="lb-trans"><h2>關於藥明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MicroVision, Inc NASDAQ: MVIS is a technology company specializing in laser scanning and sensing solutions. Founded in 1993 and headquartered in Redmond, Washington, MicroVision develops its proprietary PicoP® scanning technology, which integrates miniature lasers and microelectromechanical systems (MEMS) mirrors to create high-resolution projection displays and three-dimensional sensing systems. Over the years, the company has built a portfolio of patents and intellectual property focused on precision optics and laser-based signal processing.</p>
<div class="lb-trans"><p>藥明康德，Inc NASDAQ: MVIS 是一家專注於激光掃描和傳感解決方案的科技公司。成立於 1993 年，總部位於華盛頓州雷德蒙德，藥明康德開發了其專有的 PicoP® 掃描技術，該技術集成了微型激光器和微電機械系統（MEMS）鏡子，以創建高分辨率投影顯示和三維傳感系統。多年來，該公司建立了一系列專注於精密光學和基於激光的信號處理的專利和知識產權。</p>
</div><p>At the core of MicroVision's offerings is its display platform, which enables compact, energy-efficient projection for augmented reality (AR) headsets, head-up displays (HUDs) in automotive environments, and consumer electronics applications such as pico projectors.</p>
<div class="lb-trans"><p>藥明康德產品的核心是其顯示平台，該平台支持緊湊、節能的投影，適用於增強現實（AR）頭戴設備、汽車環境中的抬頭顯示（HUD）以及消費電子應用，如微型投影儀。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Microvision</li>
<li>CSE: ALEN.U is targeting a fast-growing digital wellness market</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>1,500 Banks Just Handed the Fed Your Bank Account</li>
<li>Your name isn't on our protected list yet</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過藥明康德</li>
<li>CSE: ALEN.U 正在瞄準快速增長的數字健康市場</li>
<li>新發現富銅的 “克拉肯” 區域</li>
<li>1,500 家銀行剛剛將你的銀行賬户交給了美聯儲</li>
<li>你的名字尚未在我們的保護名單上</li>
<li>白銀支付 20% 股息，外加 68% 股份增值</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVZJUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=MVIS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Microvision Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在藥明康德嗎？</h2>
</div><p>Before you consider Microvision, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮藥明康德之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microvision wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而藥明康德並不在名單上。</p>
</div><p>While Microvision currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然藥明康德目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

維視圖像（NASDAQ:MVIS）公佈了財報，收益每股比預期低 0.07 美元